Solitary Fibrous Tumor of the Uterus Presenting With Lung Metastases

Solitary fibrous tumour of the female genital tract: a clinicopathological analysis of 25 cases

“…Rates of metastasis were 10% (1/10) in the low‐risk tumours, 12.5% (1/8) in the moderate‐risk tumours, and 25% (1/4) in the high‐risk tumours. It is of note that case 21 is a unique case of uterine SFT that highlights the potential advantage of the Demicco model. In this case, in which the patient presented with lung metastasis, the mitotic count of the uterine tumour (1 per 10 HPFs) would not have accurately predicted clinical behaviour.…”

“…Solitary fibrous tumour is an anatomically ubiquitous fibroblastic neoplasm that occurs infrequently in the gynaecological tract. Reported cases in the literature arose throughout the female genital tract, including the vulva (nine cases [7][8][9][10][11][12][13][14], vagina (five cases [15][16][17][18][19] ), cervix (five cases [20][21][22][23][24] ), uterus (five cases [25][26][27][28][29] ), ovary (two cases 30,31 ), fallopian tube (one case 32 ), and adnexal soft tissue (two cases 33,34 ). In keeping with the above, the vulva was the most common site (14/ 25; 56%) in our cohort.…”

“…Twentyfive cases were included in our analysis, of which two (cases 7 and 21) have been previously reported. 11,29 These cases were nonetheless included in our study to analyse additional immunohistochemical staining patterns and follow-up data. Study approval was granted by the Institutional Review Board of BWH.…”

“…Solitary fibrous tumour of the female genital tract has been the subject of only a few reports, possibly because of their under‐recognition, with only 29 cases having been described, as case discussions or small case series . The goal of this study was to augment the current understanding and raise awareness of this entity through a comprehensive analysis of 25 SFTs arising in the female genital tract.…”

Uterine mesenchymal tumours: recent advances

“…Pan‐Trk immunohistochemistry can distinguish NTRK fusion‐positive uterine sarcomas from tumours with PDGFB rearrangement. CD34‐positive solitary fibrous tumours harbour NAB2–STAT6 fusion associated with signal transducer and activator of transcription‐6 (STAT‐6) expression . PDGFB fusion‐positive sarcomas should be excluded by using CD34 and PDGFB immunohistochemistry before assigning a diagnosis of UUS.…”